The vaccination plan with also the use of the AstraZeneca vaccine can start again. Even in Italy, where the prime minister Mario Draghi said he will resume vaccinating with this drug already from tomorrow.

The safety committee of theMom (Prac), at the end of the extraordinary meeting on the investigations on the AstraZeneca vaccine against Covid-19 and on thromboembolic events, which in fact reached a clear scientific conclusionExecutive Director of the European Medicines Agency, Emer Cooke, said at a press conference: This is a safe and effective vaccine and its benefits and the protection of people from Covid-19 and associated risks and hospitalizations outweigh any possible risks.

Italy will resume immediately – already tomorrow starting at 15 – the administration of the drug. This was confirmed by the national drug agency (Aifa): After hearing the Minister of Health, the Directorate General for Prevention and the Superior Health Council, Aifa announces that the reasons behind the ban no longer exist of the vaccine batches as a precautionary measure, issued on March 15, 2021. Therefore, tomorrow, as soon as the Committee for Medicinal Products for Human Use (CHMP) releases its opinion, Aifa will proceed to revoke the ban use of the AstraZeneca vaccine, thus enabling a complete resumption of the campaign vaccination starting at 15.00.

The AstraZeneca vaccine, as indicated in the EMA note, not associated with an increased overall risk of thrombosis: Thrombosis cases after administration of the AstraZeneca vaccine are lower than those occurring among the unvaccinated population, explained Sabine Straus, president of the PRAC.

As of yesterday, 7 cases of intravascular coagulation and 18 cases of thrombosis have been reported in nearly 20 million vaccinated people (25 cases in all), Straus said. Ema found no evidence of quality or batch problems. Here all the details in the in-depth analysis by the editorial staff of Health Courier.



Updated information leaflet

States can now make informed decisions, underlined the EMA, after the precautionary suspension decided by some countries (including Italy, Germany and France).

Furthermore on rare events reported after the administration of the AstraZeneca vaccine – very rare, almost all among women under the age of 55, writes the EMA in its note -, Cooke said they will be done other insights: At the moment there is no evidence that it was the vaccine that caused them. The cases under the lens are seven in Germany, three in Italy, one in Spain, two in Norway, two in India, three in Great Britain.

The EMA therefore, concluding that the safe and effective AstraZeneca vaccine and its benefits outweigh the risks, explained that consumers should be warned of the possibility of very rare thrombosis events. The AstraZeneca vaccine package insert needs to be updatedIt is important that it is communicated to the public and healthcare professionals so that they learn this information better, allowing them to mitigate these side effects.

The precautionary suspension of the vaccine

Last Monday some EU countries including Italy, France, Spain, Germany, Spain and Portugal, had decided to temporarily suspend the use of AstraZeneca doses as a precaution following some adverse events that occurred after the administration of the serum. A stop had already been decided by Denmark, Norway, Ireland and the Netherlands.

Then other countries joined. Last Tuesday at the press conference Emer Cooke reassured: We are evaluating each incident, case by case. Our experts are also meeting today (Tuesday, ed), to evaluate all the information. The experts will come to a conclusion on Thursday. And he said Era was still adamant that the benefits of the vaccine in preventing Covid-19, with the associated risks of hospitalization and death, outweigh the risks of these side effects. Furthermore, last Monday the EMA had explained that the number of overall thromboembolic events in vaccinated people it does not appear to be higher than that observed in the general population, suggesting not to interrupt the vaccination campaign.

THE ASTRAZENECA CASE: THE LATEST UPDATES

March 18, 2021 (change March 18, 2021 | 19:31)

© Time.News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.